Markets

Genmab, AbbVie Announce Data From Phase 3 EPCORE DLBCL-2 Study Of Epcoritamab Demonstrates Reduction In Disease Progression, Death By 51% For Large B-Cell Lymphoma

Oct 5, 2026 · 02:55 PM ET· updated 54m ago

Genmab A/S (NASDAQ:GMAB) and AbbVie (NYSE:ABBV) announced today positive topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating fixed treatment duration epcoritamab, a T-cell engaging bispecific antibody

Why It Matters

Two companies tested a new medicine for a serious blood cancer. The medicine cut bad outcomes in half, which is a big win for patients.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

ABBV266.71

+3.88 (+1.48%)

GMAB38.91

+4.16 (+11.97%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.